Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections

BackgroundThis study aimed to evaluate real-world data on the differences in outcomes between antiplatelet (AP) and anticoagulation (AC) therapies for intracranial arterial dissection (IAD).MethodsThis study included patients with symptomatic unruptured IAD between 2010 and 2021 that were treated wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Seong-Joon Lee, Min Kim, So Young Park, Ji Hyun Park, Bumhee Park, Woo Sang Jung, Jin Wook Choi, Yong Cheol Lim, Ji Man Hong, Jin Soo Lee
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2024.1469697/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850139194721042432
author Seong-Joon Lee
Min Kim
So Young Park
Ji Hyun Park
Bumhee Park
Bumhee Park
Woo Sang Jung
Jin Wook Choi
Yong Cheol Lim
Ji Man Hong
Jin Soo Lee
author_facet Seong-Joon Lee
Min Kim
So Young Park
Ji Hyun Park
Bumhee Park
Bumhee Park
Woo Sang Jung
Jin Wook Choi
Yong Cheol Lim
Ji Man Hong
Jin Soo Lee
author_sort Seong-Joon Lee
collection DOAJ
description BackgroundThis study aimed to evaluate real-world data on the differences in outcomes between antiplatelet (AP) and anticoagulation (AC) therapies for intracranial arterial dissection (IAD).MethodsThis study included patients with symptomatic unruptured IAD between 2010 and 2021 that were treated with anti-thrombotics. Patients were dichotomized to AC and AP based on a treatment policy analysis. Primary endpoints were a composite of ischemic early neurological deterioration, recurrent ischemic or hemorrhagic stroke, or 3-month mortality. Arterial changes were evaluated both in the early (during admission) and late (after discharge) periods. A treatment effectiveness analysis was also performed with AC, AP and a third group of antithrombotic cross-overs. Propensity score matching (PSM) was used to adjust significant baseline differences.ResultsIn unruptured IAD patients (N = 311), the AC group (N = 211) presented with a higher rate of ischemic stroke or TIA (74.4% vs. 51.0%, p < 0.001) and steno-occlusive morphology (vs. dilatation, 63.0% vs. 39.0%, p < 0.001) compared to AP group (N = 100). After PSM, there was no difference in rates of primary endpoint (9.4% vs. 6.5%, p = 0.470). The results of the treatment effectiveness analysis resembled that of the treatment policy analysis. However, there was a high rate of cross-overs from AC to AP (57/211 [27.0%]). In this group, there was a higher rate of early arterial changes (26.8% vs. 13.1%, p = 0.019) compared to the AC group.ConclusionIn patients with unruptured IAD, this study did not show differences in primary endpoints according to antithrombotic regimen, while there was a high rate of cross-overs from AC to AP.
format Article
id doaj-art-28c6ccf51e6b4ea5b7bc9caacfeb81c0
institution OA Journals
issn 1664-2295
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj-art-28c6ccf51e6b4ea5b7bc9caacfeb81c02025-08-20T02:30:23ZengFrontiers Media S.A.Frontiers in Neurology1664-22952024-12-011510.3389/fneur.2024.14696971469697Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissectionsSeong-Joon Lee0Min Kim1So Young Park2Ji Hyun Park3Bumhee Park4Bumhee Park5Woo Sang Jung6Jin Wook Choi7Yong Cheol Lim8Ji Man Hong9Jin Soo Lee10Department of Neurology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Neurology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Neurology, Ajou University School of Medicine, Suwon, Republic of KoreaOffice of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of KoreaOffice of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center, Suwon, Republic of KoreaDepartment of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Radiology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Radiology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Neurosurgery, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Neurology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Neurology, Ajou University School of Medicine, Suwon, Republic of KoreaBackgroundThis study aimed to evaluate real-world data on the differences in outcomes between antiplatelet (AP) and anticoagulation (AC) therapies for intracranial arterial dissection (IAD).MethodsThis study included patients with symptomatic unruptured IAD between 2010 and 2021 that were treated with anti-thrombotics. Patients were dichotomized to AC and AP based on a treatment policy analysis. Primary endpoints were a composite of ischemic early neurological deterioration, recurrent ischemic or hemorrhagic stroke, or 3-month mortality. Arterial changes were evaluated both in the early (during admission) and late (after discharge) periods. A treatment effectiveness analysis was also performed with AC, AP and a third group of antithrombotic cross-overs. Propensity score matching (PSM) was used to adjust significant baseline differences.ResultsIn unruptured IAD patients (N = 311), the AC group (N = 211) presented with a higher rate of ischemic stroke or TIA (74.4% vs. 51.0%, p < 0.001) and steno-occlusive morphology (vs. dilatation, 63.0% vs. 39.0%, p < 0.001) compared to AP group (N = 100). After PSM, there was no difference in rates of primary endpoint (9.4% vs. 6.5%, p = 0.470). The results of the treatment effectiveness analysis resembled that of the treatment policy analysis. However, there was a high rate of cross-overs from AC to AP (57/211 [27.0%]). In this group, there was a higher rate of early arterial changes (26.8% vs. 13.1%, p = 0.019) compared to the AC group.ConclusionIn patients with unruptured IAD, this study did not show differences in primary endpoints according to antithrombotic regimen, while there was a high rate of cross-overs from AC to AP.https://www.frontiersin.org/articles/10.3389/fneur.2024.1469697/fullintracranial dissectionischemic strokesubarachnoid hemorrhageanticoagulationantiplatelet
spellingShingle Seong-Joon Lee
Min Kim
So Young Park
Ji Hyun Park
Bumhee Park
Bumhee Park
Woo Sang Jung
Jin Wook Choi
Yong Cheol Lim
Ji Man Hong
Jin Soo Lee
Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
Frontiers in Neurology
intracranial dissection
ischemic stroke
subarachnoid hemorrhage
anticoagulation
antiplatelet
title Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
title_full Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
title_fullStr Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
title_full_unstemmed Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
title_short Comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
title_sort comparison of outcomes between anticoagulation and antiplatelet therapies for intracranial arterial dissections
topic intracranial dissection
ischemic stroke
subarachnoid hemorrhage
anticoagulation
antiplatelet
url https://www.frontiersin.org/articles/10.3389/fneur.2024.1469697/full
work_keys_str_mv AT seongjoonlee comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT minkim comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT soyoungpark comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT jihyunpark comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT bumheepark comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT bumheepark comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT woosangjung comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT jinwookchoi comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT yongcheollim comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT jimanhong comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections
AT jinsoolee comparisonofoutcomesbetweenanticoagulationandantiplatelettherapiesforintracranialarterialdissections